Solving COA Complexities in a Psoriatic Arthritis Trial

A biotechnology company and their contract research organization (CRO) partner leveraged Signant’s scale management and digital health sciences expertise to help navigate complexities related to clinical outcome assessment (COA) selection, acquisition, and implementation for a psoriatic arthritis (PsA) trial. Some of the challenges included:

• The protocol included 19 clinical outcome assessments, many of which had to be acquired and implemented electronically before FPFV.
• The primary endpoint required a composite score consisting of patient- and clinician-reported outcome measures as well as laboratory data.
• Patients had to self-report medication adherence.

Learn how our clinical and eCOA expertise helped the sponsor launch on time and ensure high-quality endpoint data for this complex trial.